A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers

NCT06034015 PHASE1 UNKNOWN

This is an integrated Phase 1, single centre, 2-part, open-label, dose-escalation study conducted in healthy volunteers to assess the safety, tolerability, and PK of APL-1501 ER capsules in comparison to APL-1202 IR tablets.

Details

Lead sponsor	Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase	PHASE1
Status	UNKNOWN
Enrolment	48
Start date	Sat Sep 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Feb 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Bladder Cancer

Interventions

• APL-1202 and APL-1501 (Single ascending dose)
• APL-1202 and APL-1501 (Multiple Ascending dose)

Countries

Australia